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Article Addendum
Mucopolysaccharidosis Type IIIA (MPSIIIA) represents an unmet 
medical need. MPSIIIA shares with 
many other lysosomal storage disorders 
(LSD) the characteristic of being a severe 
neurodegenerative disease accompanied 
by mild somatic involvement. Thus, the 
main target organ for the development 
of new treatments is the central nervous 
system (CNS), but overall clinical effi-
cacy would be greatly enhanced by simul-
taneous correction of peripheral disease. 
We have recently developed a novel treat-
ment for MPSIIIA based on the delivery 
to the cerebrospinal fluid of serotype 9 
adeno-associated virus (AAV9)-derived 
vectors. This gene therapy strategy cor-
rected both CNS and somatic pathology 
in animal models through widespread 
transduction of CNS, peripheral nervous 
system (PNS), and liver. The work set the 
grounds for the clinical translation of the 
approach to treat MPSIIIA in humans. 
Here we discuss some important consid-
erations that further support the appli-
cability of this treatment to MPSIIIA 
and other LSD with CNS and somatic 
involvement.
Introduction
Mucopolysaccharidosis Type IIIA 
(MPSIIIA), or Sanfilippo Syndrome Type 
IIIA, is an autosomic recessive neurode-
generative metabolic disease caused by the 
deficiency of sulfamidase (SGSH), a sulfa-
tase involved in the stepwise degradation 
of the glycosaminoglycan (GAG) hepa-
ran sulfate (HS).1 Sulfamidase is active 
within the lysosomes of cells, hence the 
lack of activity of this enzyme causes the 
progressive accumulation of undegraded 
forms of HS within these organelles and, 
subsequently, lysosomal and cellular dys-
function. As the genetic defect affects all 
cells of the organism, a certain degree of 
lysosomal pathology occurs in all tissues 
of the body, but the disease most serious 
clinical manifestation is progressive global 
neurodegeneration, which is accompanied 
by a mild somatic pathology.1,2 The disease 
manifests around 1–4 y of age, generally 
with delayed psychomotor development 
and behavioral problems, which are fol-
lowed by a rapid, progressive loss of cogni-
tive and motor skills.1,2 Non-neurological 
alterations include hepato- and spleno-
megaly, frequent diarrhea, recurrent ear, 
nose and throat infections, and facial dys-
morphisms.1,2 Neurological and non-neu-
rological disease worsen with age and lead 
to death of affected individuals during late 
adolescence,1,2 although in certain cases 
slower progression and extended lifespan 
have been described.3
As for most of these LSD diseases, 
there is currently no approved treatment 
for MPSIIIA, although a few therapeu-
tic strategies are currently under clinical 
investigation. Finding a cure for diseases 
that affect diffuse areas of the CNS, such 
as MPSIIIA, is challenging, mostly due 
to the presence of the blood brain barrier 
(BBB) that limits the entry to the CNS 
of systemically administered drugs.4 One 
important concept to keep in mind when 
developing a therapy for a LSD is that 
soluble lysosomal enzymes present in the 
extracellular compartment are taken up by 
mannose-6-phospate receptor (M6PR)-
mediated endocytosis into affected cells.4 
Based on this principle, the enzyme pro-
duced by one healthy cell can cross-correct 
neighboring cells carrying the disease. 
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This principle explains why for several 
LSD bone marrow transplantation repre-
sents a therapeutic option; it also explains 
why the correction of the genetic defect in 
all cells of an organ is not a requirement 
for gene therapy-based strategies, as few 
corrected cells will, in principle, secrete 
sufficient amounts of enzyme that will 
then become available to neighboring 
cells.
Among the therapies tested in MPS 
IIIA, one is the delivery of the therapeu-
tic agent directly to the CNS by periodic 
administrations of recombinant protein 
to the cerebrospinal fluid (CSF) through 
a permanently implanted intrathe-
cal delivery device (NCT01155778 and 
NCT01299727, clinicaltrials.gov). While 
this approach is technically feasible, it is 
highly invasive, and the presence of a per-
manent implant may carry risks of com-
plications such as infections. Results from 
this approach are yet to be published. A 
second approach tested is a gene transfer 
strategy in which adeno-associated virus 
(AAV)-derived vectors of serotype rh10 
(AAVrh10) encoding for the sulfamidase 
and sulfatase-modifying 1 (SUMF1) 
transgenes are delivered through multiple 
direct injections to the brain parenchyma 
(NCT01474343, clinicaltrials.gov). This 
is also a very invasive approach that fails to 
transduce the entire CNS and brain stem, 
as shown in preclinical studies for Batten 
disease.5 Long-term follow up data from 
the recently concluded MPS IIIA trial will 
help addressing this important point.
Intra-CSF Delivery  
of AAV9 Vectors as  
a New Therapeutic Approach
We recently demonstrated in animal 
models the safety and feasibility of cor-
recting whole-body MPSIIIA disease 
with a novel gene therapy strategy based 
on the delivery to the CSF of AAV9 
vectors carrying the sulfamidase gene, 
which leads to widespread transduction 
of the encephalon, spinal cord and liver 
(Fig. 1).6 Although other authors had 
found vectors in peripheral organs fol-
lowing delivery of AAV vectors to the 
CNS,7,8 an unexpected finding of our 
study was that the amount of vector that 
reached the circulation after CSF delivery 
was sufficient to mediate correction of 
MPSIIIA somatic disease. When AAV9 
vectors encoding sulfamidase were deliv-
ered through cisterna magna to MPSIIIA 
mice, an increase in sulfamidase activity 
was detected throughout the brain and 
in serum, being the liver the most impor-
tant source of circulating enzyme (Fig. 1). 
This restoration of enzymatic activity led 
to correction of GAG accumulation and 
lysosomal pathology in brain and periph-
eral organs, normalization of behavioral 
deficits and prolonged (> 24 mo) survival 
of treated animals.6 Thus, our study was 
the first to report whole-body correction 
of a lysosomal storage disease following 
CNS-directed gene therapy. Importantly, 
the pattern of distribution of the vector, 
which we believe to result from the broad 
tropism of AAV99,10 combined with CSF 
delivery, was confirmed in large animals 
models using two different routes of entry 
to the CSF (intracisternal and intracere-
broventricular vector administration). 
Moreover, we demonstrated in dogs that 
our approach could lead to the secretion 
of AAV-derived sulfamidase to the CSF, 
where it remained at high levels, in the 
absence of any signs of inflammation or 
toxicity, for the 3-mo follow-up period 
(with observation ongoing).
Our study provides the grounds for 
the clinical translation of intra-CSF deliv-
ery of AAV9-sulfamidase vectors for the 
treatment of MPSIIIA. By providing the 
sulfamidase gene to the affected cells, 
instead of administering the recombinant 
protein, the therapeutic benefit deriving 
from our proposed approach is expected 
to be long-lived, likely requiring a single 
product administration. AAV vectors have 
emerged as promising in vivo gene trans-
fer tools, showing long-term production 
of therapeutic proteins in animal models 
and in humans,11,12 with data from human 
trials accounting for therapeutic transgene 
expression up to 10 y after a single vec-
tor administration.13 On the other hand, 
the delivery of AAV vectors to the CSF 
ensures widespread, even, distribution of 
transduced cells throughout the brain and 
other important CNS structures with a 
minimally invasive procedure.
Extensive biodistribution studies in 
dogs showed that vector genomes could 
be detected in > 35 random tissue samples 
from both hemispheres of the encephalon, 
independent of the route used to deliver 
the vector to the CSF. Moreover, gene 
copy numbers ranged from 0.1 to 17 vec-
tor genomes (vg) per cell, with an aver-
age value around 2.5, evidencing a very 
homogenous distribution of the vector, 
which could be detected in deep struc-
tures such as the pons, medulla oblongata, 
and cerebellum.6 In contrast, when AAVs 
are administered to the brain parenchyma, 
and due to the limited diffusion of vec-
tors from the point of injection,5,14 the 
profile of vector distribution is uneven, 
with extremely high vector genomes at the 
point of injection but quickly decreasing 
with distance.7,15 Furthermore, as there is 
a limit to the number of injections and 
to the locations at which these injections 
can be safely performed, intraparenchy-
mal delivery fails to transduce deep CNS 
structures.14 The impossibility to target 
the cerebellum and brainstem has been 
accounted a likely culprit for the lim-
ited therapeutic efficacy observed in the 
Canavan disease trial.16
Vector Dose and Volume  
of the Target Organ
The extrapolation, by brain volume, 
of the total dose used in our mouse and 
dog studies to children results in a thera-
peutic dose of approximately 1.4 × 1014 
vg, which is considerably higher than the 
doses previously used in CNS-directed, in 
vivo gene therapy clinical trials in adult 
and pediatric populations.16-20 Assuming 
the brain as the only organ of distribution 
of the vector, and a mean brain volume 
of 1260 ml,21 our proposed clinical dose 
is 1.1 × 1011 vg/ml organ. This value is a 
slight overestimation, as it does not take 
into account the overall distribution of the 
vector, i.e., the vector genomes that do not 
transduce the brain but transduce the spi-
nal cord, dorsal root ganglia and liver. A 
similar analysis of the relationship between 
the total dose of vector administered and 
the volume of the target organ reveals that 
our proposed clinical dose is not outside 
the range of the doses used in human 
studies for which there is clear evidence of 
efficacy with excellent safety record. For 
example, in a randomized, double-blind, 
sham-surgery controlled Phase II clinical 
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trial for Parkinson disease in which a clear 
improvement in the primary endpoint 
was observed, AAV2 vectors encoding 
the glutamic acid decarboxylase (GAD) 
gene were delivered to each subthalamic 
nucleus at a dose of ~3.5 × 1010 vg.19,22 In 
Parkinson patients, the volume of the sub-
thalamic nucleus has been estimated to be 
0.13 ± 0.01ml,23 hence the dose per ml of 
target organ used in this trial was 2.7 × 
1011 vg/ml. Similarly, a small amount of 
vector (1.5 × 1011 vg) has been delivered 
to the subretinal space for the treatment 
of Leber’s congenital amaurosis due to 
RPE65 deficiency with an excellent safety 
profile and very promising outcome.24,25 
No data are available on the volume of the 
subretinal space, but if the volume of the 
whole eye were to be used for the calcula-
tion, being 6.5 ml for an adult human,26 
then the dose per ml used in this clini-
cal study was 2.3 × 1010 vg/ml. As men-
tioned before, the intra-CSF delivery of 
AAV9 vectors results in uniform distri-
bution of vector across the brain,6 which 
in theory, together with the immunologi-
cal privilege of the CNS,27 would prevent 
the development of unwanted immune 
responses. Future studies will provide evi-
dence of the safety of this gene transfer 
approach in humans.
Amenability  
for Clinical Development  
of the ICV Delivery Procedure
The route we chose to use to deliver 
vectors in our strategy maximizes correc-
tion in the disease most important target 
organ, the brain, but also provides sys-
temic therapeutic benefit through trans-
duction of a percentage of hepatocytes, 
which is sufficient to produce and secrete 
enzyme to the circulation from where it 
becomes available to all somatic organs.6 
Most importantly, we managed to achieve 
widespread transduction of the brain, the 
brainstem, the medulla oblongata, the 
cerebellum, the whole spinal cord—up 
to the cauda equina—and even all dor-
sal root ganglia of the peripheral nervous 
system with a surgical procedure than is 
minimally invasive.6 Although in proof-
of-concept studies vectors were delivered 
through intracisternal injection to mice 
and dogs, this route of administration to 
the CSF is not common in clinical pedi-
atric practice, due to the relatively smaller 
size of the cisterna in humans compared 
with animals and its proximity to vital 
centers. Thinking of the most optimal 
approach for clinical translation, and with 
the aim of increasing the safety of the 
delivery procedure, we explored the possi-
bility of administering the vectors through 
intracerebroventricular (ICV) injection, 
a technique commonly used in pediat-
ric neurosurgery.28 Although ICV access 
does require the unilateral trepanation of 
the skull (only one burr hole is needed to 
administer the vector through this route), 
the trajectory to reach the ventricle is well 
defined and goes through “mute” areas of 
the brain.28 The placement of a catheter in 
the ventricle, or ventriculostomy, is used 
for conditions such as the management of 
hydrocephalus, or for the administration 
of pharmaceuticals like oncology drugs, 
antibiotics or antifungal agents, or medi-
cations for the treatment of severe chronic 
pain, spasticity and dystonia,29 with more 
Figure 1. Schematic representation of vector and transgene product distribution following intra-cSF delivery of AAV9 vectors. the delivery of AAV9 
vectors to the cSF through unilateral administration to the lateral ventricle leads to widespread distribution of vector particles throughout the brain and 
spinal cord. in addition, some vector reaches the circulation, leading to the transduction of the liver (left). As a result of this profile of vector distribution, 
sulfamidase activity increases throughout the cnS, in the cSF and in serum, being the liver the most important source of circulating enzyme (right).
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than 40 000 procedures performed per 
year in the US alone.30 Using a surgi-
cal procedure that has been in place for 
many years provides a great safety record 
and a very well defined list of potential 
delivery-associated adverse events. It also 
simplifies clinical translation, as the tech-
nique is known to pediatric neurosurgeons 
worldwide and would not require specific 
training. One additional advantage of 
ICV administration is that by delivering 
the vector to the CSF fluid, rather than to 
the parenchyma, a relatively large volume 
of vector can be supplied within a brief 
period of time, thus shortening the dura-
tion of the surgery and providing flexibil-
ity in terms of vector concentration and 
formulation. In contrast with ICV vector 
delivery, administration of vector through 
multiple burr holes16,17 required the design 
of purpose-specific devices to deliver the 
vector within a practical time frame and 
the implementation of new neurosurgical 
techniques.14
Impact of Preexisting Immunity 
against AAV on Intra-CSF 
Delivery of Vectors
AAVs are common, non-pathogenic 
viruses and the great majority of the 
adult population has anti-AAV antibod-
ies in serum, which can greatly limit the 
efficacy of in vivo gene transfer upon sys-
temic administration.31,32 The prevalence 
and magnitude of seropositivity, however, 
varies with the AAV serotype.33 While 
~60% of the adult population has anti-
AAV2 neutralizing antibodies (NAbs) at 
high titers, only 30% of healthy individu-
als have detectable anti-AAV9 antibodies, 
and at much lower titers compared with 
AAV2.33 Other serotypes with low sero-
positivity prevalence include AAV5 and 
AAV8.33 Nonetheless, independent of the 
serotype, there seems to be a pattern of 
seroconversion with age: children under 1 
y are seronegative or seropositive at very 
low titers, then titers progressively increase 
up to around 5–6 y of age, reflecting the 
increase of socialization as children are 
scholarized, which favors natural infec-
tion by wild-type AAVs.34,35 This point is 
of utmost importance for the treatment 
of pediatric diseases with in vivo AAV 
gene therapy protocols, because a great 
percentage of the target population would 
be naïve to the vector.
In a small cohort of healthy and 
MPSIIIA-affected children we observed 
the same tendencies discussed above: 
titers against AAV2 were generally higher 
than those against AAV9 and they tended 
to increase with age in both cases, being 
the majority of children younger than 6 
y seronegative.6 Interestingly, in the same 
cohort we measured the levels of NAbs in 
matched CSF samples. In all cases, and 
independent of the serotype or the titer 
in serum, CSF titers were extremely low 
or undetectable.6 This finding suggests 
that even in diseased individuals the BBB 
integrity is maintained, or at least the 
asymmetric distribution of immunoglob-
ulins between serum and CSF is retained.
To further explore how pre-existing 
immunity could impact the therapeutic 
efficacy of intra-CSF delivery of AAV9 
vectors, we designed a very astringent 
study in which healthy dogs were pre-
immunized by systemic administration 
of non-coding AAV9. A month post-
immunization, dogs had high titers of 
anti-AAV9 in serum (1:100–1:1000). 
In contrast, titers in CSF were very low 
(1:1–1:3). At this point, dogs received an 
intra-CSF administration of AAV9 vec-
tors encoding a marker gene. Even after 
this direct CNS administration of vectors, 
the titers of NAbs in the CSF remained 
low, while the titers in serum increased 
significantly, as expected. The systematic 
evaluation of transduction revealed that 
although all somatic efficacy was lost due 
to the high levels of serum NAbs at the 
time of vector administration, most of the 
transduction in the CNS remained, with 
70–90% of encephalon and spinal cord 
samples testing positive for the presence of 
vector genome and transgene expression.6 
Although further studies are required to 
verify how the presence of pre-treatment 
low NAb titers could impact, for example, 
the levels of sulfamidase secreted to the 
CSF, these results suggest that treatment 
through intra-CSF delivery is still feasible 
in children with pre-existing immunity. 
Despite the lack of somatic efficacy, the 
minimal impact that pre-existing humoral 
immunity had on intra-CSF delivery of 
AAV9 vectors represents a clear benefit 
over other approaches that take advantage 
of AAV9’s ability to cross the BBB after 
systemic intravenous delivery.36,37
Reversibility  
in Chronic Storage Diseases
One important aspect of the experi-
mental design of our study is that we chose 
to use MPSIIIA animals that were 2 mo 
old at the time of vector administration. 
We and others had previously demon-
strated that animals already have estab-
lished disease at this age, as indicated by 
the accumulation of GAGs in the liver38 
and brain36,38,39 and the presence of neu-
roinflammation.36 Moreover, the degree 
of neuropathy is such at 2 mo of age that 
animals show clear behavioral abnormali-
ties in the open field test,40 the same test 
by which we demonstrated normaliza-
tion of behavior in treated MPSIIIA 
mice four months after intra-CSF AAV9-
sulfamidase treatment.6 The treatment-
mediated correction of behavioral deficits 
was accompanied by the disappearance 
of GAG accumulation, lysosomal pathol-
ogy and neuroinflammation in the brain, 
all of which were at the levels observed in 
healthy mice, and by normal lifespan, sug-
gesting the treatment not only prevented 
but also reverted established MPSIIIA dis-
ease. Moreover, in an unpublished study 
we observed that 4 mo after systemic 
delivery of AAV9-sulfamidase vectors to 
old (∼6 mo of age) MPSIIIA mice, GAG 
content was completely normalized in the 
brain and liver of treated animals, the 
size of the brain lysosomal compartment 
was also normal and neuroinflammation 
disappeared (Bosch et al., unpublished 
data). Given that in this study animals 
were sacrificed at an age (10 mo) at which 
untreated MPSIIIA mice already begin 
to die,36,38 the observations give further 
support to the conclusion that lysosomal 
pathology is reversible, although further 
studies are required to determine if there 
is a point of no return after which func-
tional recovery is no longer achievable 
despite the clearance of lysosomal storage. 
In agreement with our results, reversal of 
established disease following gene therapy 
has been documented in the context of 
other LSD, such as metachromatic adre-
noleukodistrophy.41 These observations 
have important implications for the future 
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clinical application of the treatment. Rare 
genetic diseases have large variability in 
clinical manifestation, and the progression 
of signs and symptoms in patients suffer-
ing from the same disease can vary sig-
nificantly from one patient to another. In 
other words, although the clinical course 
is comparable, the age at presentation 
of signs and symptoms will be variable 
between patients. Patients with a severe 
clinical form, which is the most frequent 
case among MPSIIIA patients, are diag-
nosed at an early age and mental deficit 
and loss of functions occur also at an early 
age, earlier than in patients with a more 
attenuated phenotype.2,3 Regardless of 
this variability, the majority of MPSIIIA 
patients are diagnosed between 1–4 y of 
age, once neurodegenerative disease has 
already manifested clinically.1-3 Most 
studies, however, indicate that loss of 
functions occurs at around 10 y of age.1,2,4 
If loss of function were to be considered a 
point of no return, then there is a window 
of opportunity for successful treatment of 
several years after disease diagnose.
Concluding Remarks
The in vivo delivery to the CSF of 
AAV9 vectors encoding a therapeutic gene 
holds great potential for the treatment of 
MPSIIIA and other LSD with widespread 
neurological involvment, in which the 
treatment of the CNS disease is a prior-
ity. This gene transfer strategy maximizes 
the distribution of the product in the CNS 
while minimizing delivery-associated 
risks. Additionally, the approach could 
provide clinical benefit to the somatic 
disease that often accompanies neurode-
generation in several LSD, which would 
become more relevant as patients live lon-
ger due to improved neurological outcome. 
Further studies to determine the safety, 
tolerability and potential clinical efficacy 
of this therapeutic strategy are warranted.
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